Moberg Pharma is focused on developing innovative treatments for nail fungus, with its flagship product, MOB-015, marketed under the brand name Terclara. This over-the-counter solution contains terbinafine and is designed for the treatment of mild to moderate nail fungus in adults. The product has demonstrated significant efficacy, with 76% of patients achieving a fungus-free status during phase 3 clinical trials. Terclara is currently available in 13 EU markets, and the company has established commercial partnerships that could yield potential milestone revenues of up to 70 million USD, highlighting the product's market potential and the company's commitment to addressing a widespread health issue affecting millions.

In addition to its commercial success, Moberg Pharma emphasizes the importance of patient safety and proper usage guidelines for Terclara. The company advises consulting healthcare professionals for individuals with specific health conditions, such as diabetes or immune diseases, and stresses the need for ongoing medical evaluation if symptoms persist beyond the recommended treatment duration. This focus on patient care, combined with the promising clinical results of its products, positions Moberg Pharma as a key player in the dermatological pharmaceutical market, aiming to improve the quality of life for those suffering from nail fungus.

Sweden

Moberg Pharma is a specialist pharmaceutical company focused on commercializing innovative products for the treatment of common diseases. The company's goal is to make MOB-015 the world's leading treatment for nail fungus and to build a specialty pharmaceutical company with its own sales.

Moberg Pharma

Company Details